Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
Proc Am Soc Clin Oncol 2006;24:364s. genetic makeup of the cancer, the dominant driver of growth, 3. Natale R, Bodkin D, Govindan R, et al. ZD6474 versus gefitinib in the mechanisms of resistance, the supporting environment, or patients with advanced NSCLC: final results from a two-part, double- the host that harbors it. Therefore, much in the same way we blind, randomized phase II trial (Abstract). Proc Am Soc Clin Oncol would not treat someone with breast cancer with trastuzumab 2006;24:364s. who has a FISH-negative, but erb-2 tumor defined by 1 4. Heymach J, Johnson B, Prager D, et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: follow-up results on immunohistochemistry, we should not treat someone with (Abstract). Proc Am Soc Clin Oncol 2006;24:368s. a targeted agent simply because we find the target. An 5. Fehrenbacher L, ONeill V, Belani P, et al. A phase II, multicenter, excellent example of this in NSCLC is the recent discovery of randomized clinical trial to evaluate the efficacy and safety of bevaci- the EGFR mutations and the likelihood of tumor response zumab in combination with either chemotherapy (docetaxel or pem- etrexed) or erlotinib hydrochloride compared with
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Nov 1, 2006
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.